- Home
- APRE vs ISPC Comparison
APRE vs ISPC Comparison
Compare APRE & ISPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APRE | ISPC |
|---|---|---|
| Founded | 2006 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 5.7M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | APRE | ISPC |
|---|---|---|
| Price | $0.84 | $0.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 77.0K | ★ 1.9M |
| Earning Date | 11-12-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $488,239.00 | ★ $3,352,744.00 |
| Revenue This Year | N/A | $35.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.83 | $0.26 |
| 52 Week High | $4.65 | $3.18 |
Technical Indicators
Market Signals| Indicator | APRE | ISPC |
|---|---|---|
| Relative Strength Index (RSI) | 33.19 | 49.76 |
| Support Level | $0.89 | $0.31 |
| Resistance Level | $0.91 | $0.44 |
| Average True Range (ATR) | 0.07 | 0.05 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.99 | 60.97 |
Price Performance
Historical ComparisonAbout APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.